Maria Vittoria Cossu

Dr. Maria Vittoria Cossu

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Pharmacological Research
Verified
Journal Article
Closed access
Spinello AntinoriSpinello Antinori
Spinello Antinori
Maria Vittoria CossuMaria Vittoria Cossu
Maria Vittoria Cossu
ARAnna Lisa Ridolfo
Anna Lisa Ridolfo
RRRoberto Rech
Roberto Rech
CBCecilia Bonazzetti
Cecilia Bonazzetti
MGMassimo Galli
Massimo Galli

1 June 2020 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
VMValentina Morena
Valentina Morena
LMLaura Maria Lucia Milazzo
Laura Maria Lucia Milazzo
LOLetizia Oreni
Letizia Oreni
GBGiovanna Bestetti
Giovanna Bestetti
TFTommaso Fossali
Tommaso Fossali
MCMario Corbellino
Mario Corbellino

8 September 2022 in Eurosurveillance
Verified
Journal Article
Open access
DMDavide Moschese
Davide Moschese
GPGiacomo Pozza
Giacomo Pozza
DMDavide Mileto
Davide Mileto
AGAndrea Giacomelli
Andrea Giacomelli
MCMiriam Cutrera
Miriam Cutrera
GRGiuliano Rizzardini
Giuliano Rizzardini
Anal and urethral samples from confirmed cases of monkeypox were screened for monkeypox virus (MPXV) by real-time PCR. Isolation of the virus was subsequently attempted in cell culture. Actively-replicating virus was demonstrated in 13 of 18 and 11 of 15 PCR-positive anal and urethral swabs, respectively, collected within 7 days from symptoms onset. Two asymptomatic secondary cases had detectable MPXV genetic material in urethral secretion and for one, MPXV was successfully isolated, supporting a potential MPXV sexual transmission hypothesis.

1 December 2019 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
GBGianmaria Baldin
Gianmaria Baldin
ACArturo Ciccullo
Arturo Ciccullo
SRStefano Rusconi
Stefano Rusconi
ACAmedeo Capetti
Amedeo Capetti
GSGAETANA STERRANTINO
GAETANA STERRANTINO
SGSimona Di Giambenedetto
Simona Di Giambenedetto

30 September 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ACAmedeo F. Capetti
Amedeo F. Capetti
Maria Vittoria CossuMaria Vittoria Cossu
Maria Vittoria Cossu
GOGiancarlo Orofino
Giancarlo Orofino
GSGAETANA STERRANTINO
GAETANA STERRANTINO
GCGiovanni Cenderello
Giovanni Cenderello
GRGiuliano Rizzardini
Giuliano Rizzardini
Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy. All HIV-1-infected subjects treated with DTG plus DRV/r between March 2014 and September 2015 in eight Italian centres were included in the analysis. The main metabolic data, efficacy parameters and safety data routinely collected were provided. This observational study is aimed to assess the efficacy of such approach. The primary end-point was the proportion of subjects achieving or maintaining virologic suppression <50 copies/mL at week 24. Secondary end points were maintaining virologic suppression in the follow-up (weeks 48 and 96) and safety. One hundred and thirty subjects were followed for a median of 56 months. Reasons for switching were simplification (44.6%), viral failure (30%), toxicity (16.9%), non-adherence (4.6%), persistent low-level viremia (3.1%), and drug-drug interaction (0.8%). At baseline, 118 subjects had documented resistance to 1 to 5 antiretroviral classes while 12 had viral rebound at a time when genotypic tests were not yet available. Seventeen and 14 subjects took DRV/r and DTG twice daily, respectively. One subject was lost to follow-up, one discontinued for liver enzymes’ elevation, one died of illicit drug abuse and one of cancer-related complications. The proportion of subjects with ongoing HIV replication dropped from 40% to 6.1%. Those with undetectable viral load increased from 38.5% to 76.2%. At week 48, 17.7% had HIV RNA between 1 and 49 copies/mL. The number of subjects with altered serum glucose, creatinine, ALT, AST, total-, HDL- and LDL-cholesterol, triglycerides and MDRD <90 mL/min decreased by week 48, while those having MDRD <60 mL/min remained 4.6%. Overall 90/283 baseline laboratory alterations returned to normality. Switching to DTG plus DRV/r proved to be safe, suppressing viral replication without metabolic impact.

28 January 2017 in AIDS
Verified
Journal Article
Open access
ABAlberto Borghetti
Alberto Borghetti
GBGianmaria Baldin
Gianmaria Baldin
ACAmedeo Capetti
Amedeo Capetti
GSGaetana Sterrantino
Gaetana Sterrantino
SRStefano Rusconi
Stefano Rusconi
SGSimona Di Giambenedetto
Simona Di Giambenedetto